Palacios Miriam, Tampe Ricardo, Del Campo Miguel, Zhong Ta-Ying, López Mercedes N, Salazar-Onfray Flavio, Becker María Inés
Fundación Ciencia y Tecnología para el Desarrollo (FUCITED), Avenida Eduardo Castillo Velasco 2902, Santiago 7750269, Chile.
Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, 8380453 Santiago, Chile; Millennium Institute on Immunology and Immunotherapy, Faculty of Medicine, University of Chile, 8380453 Santiago, Chile.
Eur J Med Chem. 2018 Apr 25;150:74-86. doi: 10.1016/j.ejmech.2018.02.082. Epub 2018 Feb 27.
Conjugation to carrier proteins is a way to improve the immunogenicity of peptides. Such is the case for peptides mimicking carbohydrate tumor-associated antigens in cancer vaccine development. The most used protein for this purpose is the keyhole limpet hemocyanin (KLH) from Megathura crenulata. Its limited bioavailability has prompted interest in finding new candidates; nevertheless, it is not known whether other hemocyanins might be equally efficient as carrier of carbohydrate peptide mimotopes to promotes anti-tumor responses. Here, we evaluated the carrier and antitumor activity of novel hemocyanins with documented immunogenicity obtained from Concholepas concholepas (CCH) and Fissurella latimarginata (FLH), coupled through sulfo-SMCC to P10, a mimetic peptide of GD2, the major ganglioside constituent of neuroectodermal tumors, and incorporating AddaVax as an adjuvant. The humoral immune responses of mice showed that CCH-P10 and FLH-P10 conjugates elicited specific IgM and IgG antibodies against P10 mimotope, similar to those obtained with KLH-P10, which was used as a positive control. The CCH-P10 and FLH-P10 antisera, exhibited cross-reactivity with murine and human melanoma cells, like anti-CCH and anti-FLH sera suggesting a cross-reaction of CCH and FLH glycosylations with carbohydrate epitopes on the tumor cell surfaces, similar to the KLH antisera. When mice were primed with each hemocyanin-P10 and challenged with melanoma cells, better antitumor effects were observed for FLH-P10 than for CCH-P10 and, as for KLH-P10, irrespective of conjugation. These data demonstrate that CCH and FLH are useful carriers of carbohydrate mimotopes; however, the best antitumor activity of FLH preparations, indicate that is a suitable candidate for further cancer vaccines research.
与载体蛋白偶联是提高肽免疫原性的一种方法。在癌症疫苗开发中,模拟碳水化合物肿瘤相关抗原的肽就是这种情况。为此目的最常用的蛋白质是来自皱纹盘鲍的血蓝蛋白(KLH)。其有限的生物利用度促使人们寻找新的候选物;然而,尚不清楚其他血蓝蛋白作为碳水化合物肽模拟表位的载体促进抗肿瘤反应是否同样有效。在这里,我们评估了从皱纹盘鲍(CCH)和宽缘帽贝(FLH)获得的具有免疫原性记录的新型血蓝蛋白的载体和抗肿瘤活性,通过磺基-SMCC与P10偶联,P10是神经外胚层肿瘤的主要神经节苷脂成分GD2的模拟肽,并加入AddaVax作为佐剂。小鼠的体液免疫反应表明,CCH-P10和FLH-P10偶联物引发了针对P10模拟表位的特异性IgM和IgG抗体,类似于用作阳性对照的KLH-P10所获得的抗体。CCH-P10和FLH-P10抗血清与鼠和人黑色素瘤细胞表现出交叉反应,就像抗CCH和抗FLH血清一样,表明CCH和FLH糖基化与肿瘤细胞表面的碳水化合物表位发生交叉反应,类似于KLH抗血清。当用每种血蓝蛋白-P10对小鼠进行免疫接种并用黑色素瘤细胞进行攻击时,观察到FLH-P10的抗肿瘤效果优于CCH-P10,并且对于KLH-P10,无论是否偶联,效果均如此。这些数据表明,CCH和FLH是碳水化合物模拟表位的有用载体;然而,FLH制剂的最佳抗肿瘤活性表明它是进一步癌症疫苗研究的合适候选物。